DOCSLIB.ORG

HIV VACCINE RESEARCH and DEVELOPMENT CD8 Group

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HIV VACCINE RESEARCH and DEVELOPMENT CD8 Group GLOSSARY OF KEY HIV VACCINE TERMS Immunogenicity – when attributed to a test vaccine, defines the • Since 2001, USAID has contributed $134 million to help discover an HIV vaccine. Currently, USAID is committing annual product’s ability to cause the body to produce antibodies or T-cells funding of $28 million through 2011 for HIV vaccine R&D. that may protect against an infection, disease, or foreign substance. • USAID provides support for all phases of HIV vaccine applied R&D, infrastructure, and capacity building for clinical trial Innate Immunity – a relatively nonspecific response that protects conduct, public communications, and policy analysis through a partnership with the International AIDS Vaccine Initiative. against a whole class or type of invaders but does not generate USAID does not support basic research. TECHNICAL ISSUE BRIEF immune memory (see adaptive immune response). Killer T-cells – a group of T-cells that is activated by helper T-cells • USAID plans involvement with the Global HIV/AIDS Vaccine Enterprise. PATHWAYS OF DISCOVERY: and has the ability to destroy cells infected by foreign invaders (such as viruses). Also known as cytotoxic T-cells, they may belong to the • USAID facilitates coordination between HIV vaccine clinical trial activities and HIV/AIDS prevention, care, and treatment HIV VACCINE RESEARCH AND DEVELOPMENT CD8 group. programs in developing countries. Lymphocytes – the diverse set of white blood cells (each with different functions) that are responsible for immune responses. virologists convenes twice a year to review the R&D portfolio activities. As the Global HIV/AIDS Vaccine Enterprise evolves Introduction There are two main types: B-cells (responsible for producing anti- under consideration by the organization. USAID receives its into a growing global initiative to coordinate resources, share The HIV/AIDS pandemic continues to impose a global burden, es­ bodies) and T-cells (which orchestrate various aspects of the immune proceedings and is confident in this method of intense examination technology and data, and foster greater collaboration, USAID pecially on developing countries. In the present as in the past, viral response and carry out specialized functions such as destroying cells of scientific research while exercising its authority to call upon looks forward to contributing its developing-country expertise infectious diseases are most effectively controlled – some even infected with pathogens). These cells are produced in the bone mar- additional independent external advisors as needed. All scientific to this valuable endeavor. USAID also facilitates linkages between eradicated – through prevention programs that include a vaccine. row and thymus, respectively. proposals reaching the level of IAVI’s SAC are pre-evaluated using HIV vaccine clinical trial activities in Africa and Asia and HIV/AIDS No single approach to HIV/AIDS prevention is likely to have a dra­ Memory cells – T-cells or B-cells that have been exposed to a spe- standardized selection criteria by a group of internal experts in vac- treatment, care, and prevention services under the U.S. President’s matic impact. Integrated approaches to prevention, detection, and cific invading organism and remembers the organism. Memory cells cine discovery and product development. A detailed scientific and Emergency Plan for AIDS Relief and the Global Fund to Fight AIDS, management that are tailored to specific populations yield the best help the immune system respond faster when they encounter invad- business due diligence is conducted for the proposals of interest, Tuberculosis and Malaria. results. Reversing the course of the AIDS pandemic will require ing organisms for the second time. Memory cells are long-lived sub- the intensity of which depends upon the stage of the technology carefully combined strategies that include behavioral, biomedical, sets of T-cells and B-cells that have been exposed to specific antigens platform and to what degree IAVI’s support is expected. The Chair As promising vaccine candidates are identified, USAID will provide and even surgical methods to prevent HIV, as is the case with male and can “recall” them (and then quickly mobilize an immune re- of IAVI’s SAC and its R&D management committee review each support through IAVI to assess how the availability of an HIV vac- circumcision. An effective HIV vaccine would significantly advance sponse), even if infection occurs many years later. proposal and offer their final recommendations to the senior man- cine might contribute to changing risk behavior, and how these ef- successful prevention strategies to control the AIDS pandemic. agement team. Approval from IAVI’s Board of Directors is also fects can be countered. USAID is planning for the introduction of McCLUSKEY/USAID M. Mutation – a change in the genetic material (DNA) inside a cell sought when projects require substantive organizational resources HIV vaccines in developing-country settings. These activities will YRG Care, a premiere HIV referral center in Chennai,Tamil Nadu, that results in a new characteristic. HIV is a virus that mutates and funding. The SAC subcommittees – Project Management eventually include engaging host-country governments to register Vaccine Research and Development: India, actively educates communities about HIV vaccine research in frequently as it replicates (reproduces itself), often resulting in Committee and Clinical Trials Committee – provide ongoing over- the new products, managing supply chain and logistics of vaccine A Complex Scientific Endeavor many venues. These young people are watching a play about adults a stronger and/or drug-resistant virus. being encouraged to get tested for HIV as part of participating in a sight of approved projects and their respective progress against delivery, developing protocols and training health care workers Although vaccines have proven to be among the most efficient clinical trial for a novel HIV vaccine. Neutralizing antibody – an antibody that prevents a virus from milestones on a quarterly and biannual basis. through partnerships that pre-exist in current USAID networks. tools to stop epidemics like smallpox, polio, and measles, their infecting a cell, usually by blocking viral entry points (receptors) development is neither easy nor rapid. Vaccines that are currently on the virus. Although there is little doubt about the potential for an effective administered routinely and are saving countless lives have taken up USAID’s Approach to HIV Vaccine Preclinical – testing of a vaccine or drug in cells or animals Future Directions HIV vaccine to curb the pandemic, the road to one is long and to 50 years to discover and develop. The first HIV vaccine trial Research and Development before testing in humans. Through its key partnership with IAVI and interactions with other arduous. Given the challenges, it is likely that no single candidate began in 1987; since that time, many challenges have surfaced in As an agency committed to international development and a key organizations, USAID engages in HIV vaccine R&D and related will provide a definitive solution to the pandemic. The likely sce- the pursuit of a safe and effective vaccine against the virus. If HIV par tner in the expansion of care and treatment to ease the grip T-cells – one of two main types of white blood cells critical to nario is one of discovering and mobilizing a variety of new tools to caused disease in animals the way it does in humans, testing vac­ of the pandemic, the U.S. Agency for International Development the immune system. They include CD4+ and CD8+ T-cells. The “T” stop HIV, each with its own limitations. When used in combination cines for their potential effects could be done in predictive animal (USAID) brings valuable exper tise and resources to the goal of stands for the thymus, where T-lymphocytes mature. “We must never lose sight of what a with other approaches, such as consistent condom use and partner models. Since such a reliable model does not exist for HIV, the developing a globally relevant HIV vaccine. In addition to five Virus – a microorganism composed of a piece of genetic material vaccine against HIV could accomplish. So many reduction where possible, we may be able to turn the tide against only way to confidently prove the efficacy of a candidate vaccine is decades of experience in international development and field (RNA or DNA) surrounded by a protein coat. To replicate, a virus the growing epidemic. to conduct clinical trials in people who are at risk for HIV infection. presence in nearly 100 countries, USAID has in-house exper tise have suffered for so long; the least we can do in clinical trial design and conduct, immunology, virology, product must infect a cell and direct the cellular machinery to produce is patiently focus our hopes and hard works new viruses. USAID is an established technical assistance and development The goal of all vaccines is to create an development, pharmaceutical regulator y affairs, ethics, commu­ on the science that can lead us to a promising agency with a reputable history of supporting programs to im- nity engagement and gender issues. Inevitably, more large-scale Vector – a bacterium or virus that does not cause disease in vaccine capable of diminishing this epidemic.” prove public health. Vast improvements in public health are not immunological response that can either prevent human trials are needed in developing countries to under stand humans and is used in genetically engineered vaccines
Load more

Recommended publications
  • Evaluation of T-Cell and B-Cell Epitopes and Design of Multivalent Vaccines Against Htlv-1 Diseases
    EVALUATION OF T-CELL AND B-CELL EPITOPES AND DESIGN OF MULTIVALENT VACCINES AGAINST HTLV-1 DISEASES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Roshni Sundaram, M.S. * * * * * The Ohio State University 2003 Dissertation Committee: Approved by Professor Pravin T.P. Kaumaya, Adviser Professor Christopher M. Walker Adviser Professor Neil R. Baker Department of Microbiology Professor Marshall V. Williams ABSTRACT Human T-cell lymphotropic virus type I (HTLV-1) is a C type retrovirus that is the causative agent of an aggressive T-cell malignancy, adult T-cell leukemia/lymphoma (ATLL). The virus is also implicated in a number of inflammatory disorders, the most prominent among them being HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP). HTLV-1, like many viruses that cause chronic infection, has adapted to persist in the face of an active immune response in infected individuals. The viral transactivator Tax is the primary target of the cellular immune response and humoral responses are mainly directed against the envelope protein. Vaccination against HTLV-1 is a feasible option as there is very little genetic and antigenic variability. Vaccination regimes against chronic viruses must be aimed at augmenting the immune response to a level that is sufficient to clear the virus. This requires that the vaccine delivers a potent stimulus to the immune system that closely resembles natural infection to activate both the humoral arm and the cellular arm. It is also clear that multicomponent vaccines may be more beneficial in terms of increasing the breadth of the immune response as well as being applicable in an outbred population.
    [Show full text]
  • Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues
    Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues September 1995 OTA-BP-H-163 GPO stock #052-003-01429-7 Recommended Citation: U.S. Congress, Office of Technology Assessment, Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues, OTA-BP-H-163 (Washington, DC: U.S. Government Printing Office, September 1995). oreword IDS researchers are investigating new vaccines that would prevent infection with HIV and reduce the spread of AIDS. Some have argued that product liabil- ity concerns have discouraged investment in HIV vaccine research and devel- opment. The purpose of this OTA background paper is to describe the current state of development of HIV vaccines, and to discuss what is known about adverse reac- tions that may occur. The background paper provides an overview of ethical issues that arise in the conduct of HIV vaccine trials. The report also discusses alternatives to the current product liability system to encourage the development of HIV vaccines and to fairly compensate those who are harmed as a result of adverse reactions to the vaccine. This background paper was prepared in response to a request from the Subcommittee on Health of the House Ways and Means Committee. It is eleventh in OTA’s series of studies on HIV-related issues. The preceding papers in this series were: Do Insects Transmit AIDS? (9/87), AIDS and Health Insurance: An OTA Survey (2/88), How Effective is AIDS Education? (6/88), The Impact of AIDS on the Kaiser Permanente Medical Care Program (Northern California Region) (7/88), How Has Federal Research on AIDS/HIV Disease Contributed to Other Fields? (4/90), The Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection (9/90), HIV in the Health Care Workplace (11/91), The CDC’s Case Definition of AIDS: Implications of the Proposed Revisions (8/92), Difficult-to-reuse Needles for the Prevention of HIV Infection Among Injecting Drug Abusers (10/92), and External Review of the Federal Centers for Disease Control and Prevention’s HIV Prevention Programs (9/94).
    [Show full text]
  • Evolution of the PRD1-Adenovirus Lineage: a Viral Tree of Life Incongruent with the Cellular 3 Universal Tree of Life 4 5 Authors 6 Anthony C
    bioRxiv preprint doi: https://doi.org/10.1101/741942; this version posted August 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title 2 Evolution of the PRD1-adenovirus lineage: a viral tree of life incongruent with the cellular 3 universal tree of life 4 5 Authors 6 Anthony C. Woo1,2*, Morgan Gaia1,2, Julien Guglielmini3, Violette Da Cunha1,2 and Patrick 7 Forterre1,2* 8 9 Affiliations 1 10 Unité de Biologie Moléculaire du Gène chez les Extrêmophiles (BMGE), Department of 11 Microbiology, Institut Pasteur, 25-28 Rue du Docteur Roux, 75015 Paris, France. 2 12 Department of Microbiology, CEA, CNRS, Université Paris-Sud, Université Paris-Saclay, 13 Institute for Integrative Biology of the Cell (I2BC), Bâtiment 21, Avenue de la Terrasse, 14 91190 Gif-sur-Yvette cedex, France. 3 15 HUB Bioinformatique et Biostatistique, C3BI, USR 3756 IP CNRS, Institut Pasteur, 25-28 16 Rue du Docteur Roux, 75015 Paris, France 17 *corresponding authors: 18 Anthony Woo: [email protected] 19 Patrick Forterre: [email protected] 20 21 Abstract 22 Double-stranded DNA viruses of the PRD1-adenovirus lineage are characterized by 23 homologous major capsid proteins containing one or two β-barrel domains known as the jelly 24 roll folds. Most of them also share homologous packaging ATPases of the FtsK/HerA 25 superfamily P-loop ATPases. Remarkably, members of this lineage infect hosts from the three 26 domains of life, suggesting that viruses from this lineage could be very ancient and share a 27 common ancestor.
    [Show full text]
  • Coversheet for Thesis in Sussex Research Online
    A University of Sussex DPhil thesis Available online via Sussex Research Online: http://eprints.sussex.ac.uk/ This thesis is protected by copyright which belongs to the author. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Please visit Sussex Research Online for more information and further details Knowledge Accumulation and Vaccine Innovation: Lessons from Polio and HIV/AIDS Ohid Yaqub Doctor of Philosophy University of Sussex Submitted in September 2008 ii I hereby declare that this thesis has not been submitted, either in the same or different form, to this or any other university for a degree. Ohid Yaqub iii To my parents and Corinne, Two worlds that should not be separate. iv ACKNOWLEDGEMENTS This thesis was funded by the Economic and Social Research Council and supervised by Paul Nightingale. Paul is a supervisor who is extremely generous with his time, ideas and encouragement; and who manages to make academia look extremely fun. His energy and enthusiasm were most important to me when I really thought the ship was sinking. I cannot thank him enough and feel privileged to have worked with him. My first opportunity to pursue some of the ideas in this thesis was under the supervision of Ed Steinmueller and Aldo Geuna.
    [Show full text]
  • A Brief Speculative History of Avipoxvirus in New Zealand
    A brief, speculative history of avipoxvirus in New Zealand Brett Gartrell, Laryssa Howe, Maurice Alley, Hye-Jeong Ha Intro to avipoxvirus (APV) • Global distribution • Reports in >280 bird species, 70 families, 20 orders globally • Economic losses in domestic poultry • Biodiversity losses in island ecosystems (Hawaii, Galapagos, Canary Islands) in conjunction with avian malaria (vaccinia virus, copyright E. Niles). APV infection characteristics • Excellent environmental stability • Need a break in the epithelium for infection to establish • Insect and mechanical vectors are main route of infection • Host specificity varies between strains APV molecular characteristics • Fowlpox virus is the type species of the Avipoxvirus genus • complete genomic sequences of Fowlpox virus and Canarypox virus • The two genomes are highly diverged, sharing only ca. 70% sequence identity • The 365-kbp genome of Canarypox virus is larger than that of Fowlpox virus (288 kbp) and shows significant differences in gene content APV phylogeny • Initially assigned strain/species status on host affected but confused by multi-host pathogenic strains • DNA sequences of the 4b core protein coding genomic region currently used. • Wide variation in genome has limited other pan-genus PCR primers • the vast majority of avian poxvirus isolates clustered into three major clades, represented by the Fowlpox virus (clade A), the Canarypox virus (clade B), and the Psittacinepox virus (clade C) APV phylogeny from NZ birds (HJ Ha PhD) Silvereye © P Sorrell Ha, H.J., Howe, L., Alley, M., Gartrell, B. 2011. The phylogenetic analysis of avipoxvirus in New Zealand. Veterinary Microbiology 150: 80–87 APV distribution in NZ Ha, H.J., Howe, L., Alley, M., Gartrell, B.
    [Show full text]
  • Genomic Characterisation of a Novel Avipoxvirus Isolated from an Endangered Yellow-Eyed Penguin (Megadyptes Antipodes)
    viruses Article Genomic Characterisation of a Novel Avipoxvirus Isolated from an Endangered Yellow-Eyed Penguin (Megadyptes antipodes) Subir Sarker 1,* , Ajani Athukorala 1, Timothy R. Bowden 2,† and David B. Boyle 2 1 Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Melbourne, VIC 3086, Australia; [email protected] 2 CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, VIC 3220, Australia; [email protected] (T.R.B.); [email protected] (D.B.B.) * Correspondence: [email protected]; Tel.: +61-3-9479-2317; Fax: +61-3-9479-1222 † Present address: CSIRO Australian Animal Health Laboratory, Australian Centre for Disease Preparedness, Geelong, VIC 3220, Australia. Abstract: Emerging viral diseases have become a significant concern due to their potential con- sequences for animal and environmental health. Over the past few decades, it has become clear that viruses emerging in wildlife may pose a major threat to vulnerable or endangered species. Diphtheritic stomatitis, likely to be caused by an avipoxvirus, has been recognised as a signifi- cant cause of mortality for the endangered yellow-eyed penguin (Megadyptes antipodes) in New Zealand. However, the avipoxvirus that infects yellow-eyed penguins has remained uncharacterised. Here, we report the complete genome of a novel avipoxvirus, penguinpox virus 2 (PEPV2), which was derived from a virus isolate obtained from a skin lesion of a yellow-eyed penguin. The PEPV2 genome is 349.8 kbp in length and contains 327 predicted genes; five of these genes were found to be unique, while a further two genes were absent compared to shearwaterpox virus 2 (SWPV2).
    [Show full text]
  • Safety of Intravenous Administration of a Canarypox Virus Encoding The
    Cancer Gene Therapy (2003) 10, 509–517 r 2003 Nature Publishing Group All rights reserved 0929-1903/03 $25.00 www.nature.com/cgt Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients Anand G Menon,1 Peter JK Kuppen,1 Sjoerd H van der Burg,2 Rienk Offringa,2 Marie Claude Bonnet,5 Bert IJ Harinck,1 Rob AEM Tollenaar,1 Anke Redeker,2 Hein Putter,4 Philippe Moingeon,5 Hans Morreau,3 Cornelis JM Melief,2 and Cornelis JH van de Velde1 1Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, The Netherlands; 3Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 4Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands; and 5Aventis Pasteur, Lyon, France. Overexpression of p53 occurs in more than 50% of colorectal cancers. Therefore, p53 represents an attractive target antigen for immunotherapy. We assessed the safety of a canarypox virus encoding the human wild-type p53 gene given intravenously to end- stage colorectal cancer patients in a three-step dose escalation study aimed at inducing p53 immune responses. Patients with metastatic disease of p53-overexpressing colorectal cancers were vaccinated three times at 3-week intervals, each time with 106.5 7.0 7.5 CCID50 (CCID50 ¼ cell culture infectious dose 50%; group 1, n ¼ 5), 10 CCID50 (group 2, n ¼ 5) or 10 CCID50 (group 3, n ¼ 6). Vital signs and the occurrence of adverse events were monitored and blood was analyzed for biochemical and hematological parameters as well as signs of auto-immune safety.
    [Show full text]
  • Avian Pox in Shearwaters on Lord Howe Island
    Association of Avian Veterinarians Australasian Committee Ltd. Annual Conference Proceedings Auckland New Zealand 2017. 25: 63-68. Avian Pox in Shearwaters on Lord Howe Island Subir Sarker1, Shubhagata Das2, Jennifer L. Lavers3, Ian Hutton4, Karla Helbig1, Chris Upton5, Jacob Imbery5, and Shane R. Raidal2 1. Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Melbourne, VIC, 3086 2. School of Animal and Veterinary Sciences, Charles Sturt University, NSW 2678 3. Institute for Marine and Antarctic Studies, University of Tasmania, TAS 7004 4. Lord Howe Island Museum, Lord Howe Island, NSW 2898 5. Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada. Abstract fungal infections are common and contribute to mortality (van Riper and Forrester, 2007). Until recently six avipox- Avipoxvirus infections occur in a wide range of bird spe- virus genomes were published; a pathogenic American cies worldwide. In Australia pox is common in the Aus- strain of Fowlpox virus (Afonso et al., 2000), an attenuat- tralian magpie (Cracticus tibicen), Currawongs (Strepera ed European strain of Fowlpox virus (Laidlaw and Skinner spp.) and Silvereyes (Zosterops lateralis) but very little , 2004), a virulent Canarypox virus (Tulman et al., 2004), a is known about the evolution of this family of viruses pathogenic South African strain of Pigeonpox virus, a Pen- or the disease ecology of avian poxviruses in seabirds. guinpox virus (Offerman et al., 2014) and a pathogenic Pox lesions have been seen in colonies of Shy Albatross Hungarian strain of Turkeypox virus (Banyai et al., 2015). (Thalassarche cauta) in Bass Strait but the epidemiology of pox in pelagic birds is not very well elucidated.
    [Show full text]
  • Developing a Vaccine Against HIV Infection
    Developing a vaccine against HIV infection KEY POINTS Researchers have been working on an HIV vaccine since the 1980s, but progress towards an effective vaccine has been much slower than anticipated. Finding at least a partially effective vaccine remains of critical importance for the HIV response. The biggest reduction in new infections would be achieved by a combination of PrEP, universal antiretroviral treatment for people already living with HIV, and a vaccine.1 An HIV vaccine is a more realistic prospect today than a decade ago and an optimistic forecast of HIV vaccine availability is that one might be available by 2030. Explore this page to find out more about the need for a vaccine against HIV, challenges in vaccine development, progress in developing a vaccine and achieving an effective vaccine for HIV. What is an HIV vaccine? Today, an effective vaccine against HIV does not exist. A vaccine that can prevent infection would teach the immune system to respond to HIV by making antibodies that can bind to the virus and stop it from infecting cells, or by promoting other immune responses that kill the virus. No vaccine is 100% effective, and this is likely to be the same for HIV. Some people who receive a vaccine will not respond strongly enough to the vaccine and will not be protected, as in the case of the seasonal flu vaccine. But finding at least a partially effective vaccine remains of critical importance for the HIV response, as all successful disease elimination strategies have included a vaccine among their arsenal. The need for a vaccine against HIV UNAIDS estimates that 1.8 million people became infected with HIV in 2017, 36.9 million people were living with HIV and 21.7 million were receiving antiretroviral therapy.
    [Show full text]
  • Status of HIV Vaccine Research & Development
    Status of HIV Vaccine Research & Development Wayne C. Koff, Ph.D. Chief Scientific Officer, IAVI Global Vaccine Immunization Research Forum Bethesda, Maryland March 4, 2014 HIV continues to devastate…. 35.3 million people living with HIV worldwide 2.3 million new infections in 2012 ; 2012 2008 6,300 new HIV infections daily 33 million 35.3 million 36 million AIDS-related deaths to date 2005 32 million Women bear the brunt of the epidemic, representing almost 60% of HIV-infected adults in Africa and half of adults worldwide 2000 28.5 million Since the beginning >70,000,000 HIV Infections 1995 18.5 million 1990 7.5 million people living with HIV Remarkable scale up of treatment; however, doesn’t solve problem. Lifetime treatment required and for every (1) person put on treatment, (2) are newly infected. THE WORLD NEEDS AN HIV VACCINE Source: Joint United Nations Programme on HIV/AIDS Public Health Impact: A Vaccine Is Needed to “Get Close to Zero” Cumulative infections avoided 2011-50 22.5M 16.0M New HIV Infections HIV New 7.4M * An illustrative vaccine with an assumed efficacy of 60%, not representative of any specific candidate in development. Coverage reaches 70% in generalized HIV/AIDS epidemics, 60% in concentrated epidemics. Potential impact of an AIDS vaccine as part of the UNAIDS Enhanced Investment Framework, IFE Modeling project – UNAIDS, Futures Institute, IAVI, AVAC [funded by USAID] 3 AIDS vaccine development: Scientific Challenges 1. HIV variability 2. Lack of an ideal animal model 3. Natural immunity fails to clear HIV 4. HIV is a retrovirus- integrates into the host genome- short window of opportunity to control 5.
    [Show full text]
  • Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward
    AIDS PATIENT CARE and STDs Volume 29, Volume 7, 2015 ª World Health Organization 2015 DOI: 10.1089/apc.2014.0348 Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward Ying-Ru Lo, MD,1 Carissa Chu, BS,2,3 Jintanat Ananworanich, MD, PhD,4,5 Jean-Louis Excler, MD,4,5 and Joseph D. Tucker, MD, PhD, MA3,6 Abstract Clinical and basic science advances have raised considerable hope for achieving an HIV cure by accelerating research. This research is dominated primarily by issues about the nature and design of current and future clinical trials. Stakeholder engagement for HIV cure remains in its early stages. Our analysis examines timing and mechanisms of historical stakeholder engagement in other HIV research areas for HIV-uninfected indi- viduals [vaccine development and pre-exposure prophylaxis (PrEP)], and HIV-infected individuals (treatment as prevention, prevention of mother-to-child transmission, and treatment of acute HIV infection) and articulate a plan for HIV cure stakeholder engagement. The experience from HIV vaccine development shows that early engagement of stakeholders helped manage expectations, mitigating the failure of several vaccine trials, while paving the way for subsequent trials. The relatively late engagement of HIV stakeholders in PrEP research may partly explain some of the implementation challenges. The treatment-related stakeholder engagement was strong and community-led from the onset and helped translation from research to implementation. We outline five steps to initiate and sustain stakeholder engagement in HIV cure research and conclude that stakeholder engagement represents a key investment in which stakeholders mutually agree to share knowledge, benefits, and risk of failure.
    [Show full text]
  • A History of AIDS: Looking Back to See Ahead
    S94 Warner C. Greene Eur. J. Immunol. 2007. 37: S94–102 Breakthroughs in Immunology A history of AIDS: Looking back to see ahead Warner C. Greene Gladstone Institute of Virology and Immunology, University of California, Received 5/7/05 San Francisco, CA, USA Revised 22/8/07 Accepted 4/9/07 [DOI 10.1002/eji.200737441] Since breaking onto the scene 26 years ago, HIV has proven an indefatigable foe. Over 60 million people have been infected with this retrovirus, and 25 million have already died of AIDS. HIV infection is hitting the hardest in the developing world [1]. Tragically, Key words: 1600 babies continue to acquire HIV every day from their infected mothers. Over 12 AIDS Á Drug design/ million children have also been orphaned by AIDS, and this number will likely double by discovery Á Global 2010. With these sobering statistics as a backdrop, this feature traces the history of the pandemic Á HIV devastating HIV/AIDS pandemic and offers a view for what the future may hold. Á Infectious diseases Unfolding of a pandemic The appearance of AIDS in Haiti fueled speculation that the disease had originated there. Although not compell- ing, these theories stoked the fear and prejudice AIDS was first recognized in the summer of 1981 surrounding the disease. (Table 1). Young gay men began falling ill and dying of By late 1982, epidemiologic evidence indicated that opportunistic infections their immune systems should AIDS was an infectious disease transferred by bodily have fended off [2]. Those afflicted became emaciated fluids and by exposure to contaminated blood or blood and often developed dark purple lesions on their arms products [3].
    [Show full text]